Derivatives of aryl hydrocarbon receptor agonists
A compound having one of the following structures of Formula (IV) or (V): or a stereoisomer, salt, or tautomer thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 R 6 , R 7 , R 8 , R 10 , R 11a R 11b , R 12a R 12b , X, Y, and Z are as defined herein. Pharmaceutical composition comprising the compounds, and their use in methods of treating diseases are also described.
1 . A method of treating an inflammatory disease, comprising:
administering a compound of Formula (IV) or (V) to a subject in need thereof:
or a stereoisomer, salt, or tautomer thereof, wherein:
R 1 , R 2 , R 3 , R 4 , R 5 R 6 , R 7 , and R 8 , are each independently hydrogen, deuterium, alkyl, halo, perfluoroalkyl, alkynyl, alkenyl, alkoxy, cycloalkoxy, thioalkyl, thiocycloalkoxy, perfluoroalkoxy, perfluorothioalkyl, hydroxyl, ester, amido, carboxyl, carbamoyl, sulfonyl amido, acylsulfonyl amido, sulfonyl, sulfinyl, sulfonyl urea, amino, thioester, nitrile, nitro, azido, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
R 11a is halo, 4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, —OH, —OX—, —SX—, —S(O) 2 X—, —NX 2 —, —OC(═O)X—, or —OC(═O)NX 2 —;
R 11b is 4-8 membered heterocycloalkyl, 5-8 membered heteroaryl, or —NX 2 —, wherein the 4-8 membered heterocycloalkyl of R 11a or R 11b is optionally substituted;
X is each independently hydrogen, C 1 -C 10 alkyl, C 2 -C 10 alkenyl, C 1 -C 6 haloalkyl, C 1 -C 10 heteroalkyl, —S(O) 2 OH, aryl, or 3-8 membered heterocycloalkyl;
wherein the C 1 -C 10 alkyl and C 1 -C 10 heteroalkyl are optionally substituted with carboxyl, —NHS(═O) 2 Y—, —NHC(═O)OY—, or —NHC(═O)Y—;
wherein the 3-8 membered heterocycloalkyl of X is optionally substituted with C 1 -C 6 alkyl, C 1 -C 4 amino, halo, —C(═O)Y—, or —C(═O)OY—;
Y is each independently H, C 1 -C 6 perfluoroalkyl, or C 1 -C 6 alkyl;
R 12a and R 12b , are each independently hydrogen or C 1 -C 6 alkyl;
R 10 is O, NZ, or NNZ 2 ; and
Z is each independently hydrogen, hydroxyl, aryl, or C 1 -C 4 alkyl, wherein C 1 -C 4 alkyl is optionally substituted with aryl,
wherein the inflammatory disease is an inflammatory bowel disease.
2 . The method of claim 1 , wherein the 4-8 membered heterocycloalkyl of R 11a or R 11b is azetidinyl, diazetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, diazinyl, triazinyl, azepanyl, diazepanyl, azocanyl, oxetanyl, dioxetanyl, tetrahydrofuranyl, dioxolanyl, oxanyl, dioxanyl, trioxanyl, oxepanyl, oxocanyl, phosphetanyl, phospholanyl, phosphinanyl, thietanyl, dithietanyl, tetrahydrothiophenyl, dithiolanyl, thianyl, dithianyl, trithianyl, thiepanyl, thiocanyl, oxathiolidinyl, isoxthiolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, morpholinyl, thiomorpholinyl, or oxathianyl.
3 . The method of claim 1 , wherein the 5-8 membered heteroaryl of R 11a or R 11b is pyrrole, furan, thiophene, pyridine, azonine, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, diazine, triazine, tetrazine, pentazine, or diazepine.
4 . The method of claim 1 , wherein R 11a of the compound has one of the following structures:
5 . The method of claim 1 , wherein R 11b is —NX 2 -.
6 . The method of claim 5 , wherein R 11b of the compound has one of the following structures:
7 . The method of claim 1 , wherein each of R 12a and R 12b are hydrogen.
8 . The method of claim 1 , wherein R 10 has one of the following structures:
9 . The method of claim 1 , wherein R 1 , R 2 , R 3 , R 4 , R 5 R 6 , R 7 , and R 8 , are each independently hydrogen, deuterium, alkyl, halo, or perfluoroalkyl.
10 . The method of claim 1 , wherein the compound is selected from the group consisting of:
11 . The method of claim 10 , wherein the compound has one of the following structures:
12 . The method of claim 1 , wherein the inflammatory bowel disease is selected from the group consisting of ulcerative colitis pouchitis and Crohn's disease.
13 . The method of claim 1 , wherein the inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.
14 . The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.